secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERACYTE, INC. (VCYT)
CIK:        0001384101
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001384101-25-000128
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Veracyte Q3 revenue up 14% to $131.9M, raises FY guidance; adjusted EBITDA margin 30%
--------------------------------------------------------------------------------

- Total revenue $131.9M (+14% YoY); testing rev $127.8M (+17%); GAAP net income $19.1M.
- Decipher revenue $82.2M (+26%); Afirma $43.2M (+7%); total testing volume +19% to 43,679.
- Adjusted EBITDA $39.7M (30% margin); cash from ops $44.8M; cash & equivalents $366.4M.
- Raised FY2025 total revenue guidance to $506-510M; testing rev guidance $484-487M (+16%).
- Completed enrollment of Percepta Nasal Swab NIGHTINGALE trial; upcoming TrueMRD and Prosigna LDT launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1384101/000138410125000128/0001384101-25-000128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1384101/000138410125000128/vcyt-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001384101-25-000128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer